Novartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on track, after the FDA rejected it last year, by changing the factory that makes the drug.

Novartis and NHS England have forged a pact to accelerate the access of its new cholesterol-lowering drug inclisiran for primary prevention of cardiovascular disease. Health Secretary Matt Hancock ...

Provident Financial Services Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View PFS financial statements in full.

Dual primary endpoints are PFS (RECIST v1.1, blinded independent central review) and OS by tumor PD-L1 expression (CPS ≥10 and ≥1) and in all pts. PFS was estimated using the Kaplan-Meier method.

In IMPROVE IT (Improved Reduction of Outcomes; Vytorin Efficacy International Trial), addition of ezetimibe to simvastatin 40 mg daily in patients <10 days after ACS led to a modest but significant ...

The latest Peak Rare Earths Limited [PEK] news, articles, data and analysis from The Australian Financial Review ...